What is SciBase?
SciBase AB operates at the intersection of advanced engineering and clinical dermatology. Its flagship product, Nevisense, represents a paradigm shift in the non-invasive evaluation of skin disorders, including malignant melanoma and atopic dermatitis. By leveraging EIS technology, the device provides clinicians with objective data to categorize cellular structures, effectively reducing the subjectivity inherent in traditional visual skin assessments. With regulatory milestones achieved across Europe, Australia, and the United States, SciBase has successfully transitioned from a research-heavy entity to a publicly traded commercial enterprise on the First North Growth Market. The company's commitment to evidence-based medicine is anchored by its extensive clinical study data, which remains a cornerstone of its market differentiation strategy.
How much funding has SciBase raised?
SciBase has raised a total of $2.1M across 1 funding round:
Debt
$2.1M
Debt (2025): $2.1M with participation from Castle Biosciences
Key Investors in SciBase
Castle Biosciences
A diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.
What's next for SciBase?
With this recent strategic financing, SciBase is positioned to accelerate its market penetration and operational scaling. The focus will likely shift toward expanding the clinical utility of the Nevisense platform beyond melanoma detection, specifically targeting the assessment of skin barrier function and inflammatory conditions. As the company continues to integrate its technology into standard clinical workflows, the management team will likely prioritize strengthening its commercial infrastructure in key international markets. This capital deployment is essential for maintaining the company's competitive edge in the medical device sector, ensuring that its diagnostic tools remain at the forefront of dermatological care while driving long-term value for shareholders.
See full SciBase company page
